Zacks Investment Research upgraded shares of Achillion Pharmaceuticals (NASDAQ:ACHN) from a sell rating to a hold rating in a research note published on Thursday.
According to Zacks, “Achillion has no approved product in its portfolio and focuses on developing small molecule therapeutics to treat infectious and complement-mediated diseases. The company has shown progress in developing Factor D inhibitors. The lead candidate, ACH-4471 has shown clinically meaningful complement inhibition of factor D in PNH patients. Meanwhile, another factor D inhibitor candidate was advanced to phase I study in 2017. Though this area has commercial opportunity the complement-mediated space is highly crowded as many biotech companies are working on bringing these treatments to market. In a major setback, J&J terminated its HCV agreement in September 2017 and Achillion lost a strong and experienced partner and major source of funds. Meanwhile, shares have outperformed the industry so far this year.”
Several other equities analysts have also recently commented on the company. Barclays upgraded Achillion Pharmaceuticals from an underweight rating to an equal weight rating and set a $5.00 target price for the company in a research note on Monday, May 21st. ValuEngine upgraded Achillion Pharmaceuticals from a sell rating to a hold rating in a research note on Friday, June 1st. Finally, BidaskClub upgraded Achillion Pharmaceuticals from a hold rating to a buy rating in a research note on Tuesday, March 6th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus price target of $4.88.
Shares of NASDAQ:ACHN opened at $2.86 on Thursday. Achillion Pharmaceuticals has a 52-week low of $2.58 and a 52-week high of $5.66. The company has a market capitalization of $377.67 million, a price-to-earnings ratio of -4.61 and a beta of 0.86.
Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings data on Wednesday, May 2nd. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.01). equities research analysts forecast that Achillion Pharmaceuticals will post -0.56 EPS for the current fiscal year.
Institutional investors have recently added to or reduced their stakes in the company. RTW Investments LP lifted its stake in Achillion Pharmaceuticals by 72.8% during the fourth quarter. RTW Investments LP now owns 13,546,902 shares of the biopharmaceutical company’s stock worth $39,015,000 after purchasing an additional 5,707,136 shares during the last quarter. BlackRock Inc. lifted its stake in Achillion Pharmaceuticals by 17.7% during the fourth quarter. BlackRock Inc. now owns 11,572,015 shares of the biopharmaceutical company’s stock worth $33,326,000 after purchasing an additional 1,736,124 shares during the last quarter. BVF Inc. IL bought a new position in Achillion Pharmaceuticals during the fourth quarter worth $4,632,000. Dimensional Fund Advisors LP lifted its stake in Achillion Pharmaceuticals by 27.8% during the first quarter. Dimensional Fund Advisors LP now owns 6,042,463 shares of the biopharmaceutical company’s stock worth $22,418,000 after purchasing an additional 1,314,880 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Achillion Pharmaceuticals by 128.8% during the fourth quarter. Renaissance Technologies LLC now owns 2,182,467 shares of the biopharmaceutical company’s stock worth $6,286,000 after purchasing an additional 1,228,492 shares during the last quarter. Institutional investors own 80.71% of the company’s stock.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.
Get a free copy of the Zacks research report on Achillion Pharmaceuticals (ACHN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.